A Trial to Evaluate the Pharmacokinetics of ABL001 in Healthy and Hepatic Impaired Subjects

Key Inclusion criteria:

- Body mass index of 18-36 kg/m2, with body weight 50 kg and no more than 120 kg

- Vital signs (after at least 3 minutes rest in the supine position) within the
following ranges (inclusive):

- Oral body temperature between 35.0 °C - 37.5 °C (95.0-99.5°F)

- Systolic BP ≥90 mmHg and ≤140 mmHg

- Diastolic BP ≥60 mmHg and ≤90 mmHg for healthy subjects and 50-100 mmHg for
subjects with impaired hepatic function (groups 2-4)

- Pulse Rate: ≥50 and ≤90 bpm for healthy subjects (group 1) and ≥50 and ≤100 bpm
for subjects with impaired hepatic function (groups 2-4)

- Healthy subjects with no clinically significant abnormalities as determined by past
medical history, physical examination, vital signs, ECG, and clinical laboratory test

- Subjects with Child-Pugh Clinical Assessment Score as calculated per the Child-Pugh
classification

Key Exclusion Criteria:

- Presence of clinically significant ECG abnormalities or a family history or presence
of prolonged QT-interval syndrome

- History of cardiac disease

- Sexually active males must use a condom during intercourse while taking the drug and
for 7 days after stopping

- Any surgical or medical condition which might significantly alter the absorption,
distribution, metabolism or excretion of drugs

- Administration of strong or moderate CYP3A4 inhibitors or inducers (including St
John's wort) within 14 days prior to dosing

Other protocol-defined inclusion/exclusion criteria may apply.